Bayer, J&J land top 10 spots in brand power ranking

Tenet Partners is out with its ninth annual evaluation of the most powerful brands, and a pair of pharmas locked up top spots on the list.

Bayer finished at No. 3 for the second year in a row, while Johnson & Johnson finished in eighth place. But J&J actually dropped two positions from last year's No. 6 performance, making it the biggest decliner among the top 10 brands.

The drugmakers are in well-known company: Coca-Cola finished first for the ninth time in the study--which includes interviews with 10,000 global business executives--followed by Hershey at No. 2.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

As Tenet notes, while a brand is considered an intangible asset, it is one of the most important assets a company owns. Intangible assets in general make up about 84% of the total value of S&P 500 companies, according to 2015 research by Ocean Toma.

And Bayer is on the up-and-up. It gained in favorability, a measurement of positive brand perception, in Tenet’s 2016 review after dropping in 2015.

While J&J did lose ground in brand power this year, it also finished at No. 6 in Tenet’s absolute brand value calculations. “… In our view, BrandPower is a measure of brand strength, based on successful brand management, and independent of brand value. By contrast, brand valuation is the output of a time-tested statistical model, measuring the impact of a company’s brand in the context of its financial performance," Tenet wrote in its report.

- read the news release

Related Articles:
Brand matters: Interbrand's best in pharma ranks Pfizer, Roche and Merck at top
Pfizer and Valeant jump in annual brand analysis, but most other pharmas drop
They're no Coca-Cola, but top biopharma brands Pfizer, Biogen and Merck still worth billions
Bayer, GSK, Novo and Roche rank in top 10 for online comms

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.